Abstract:Commercial coenzyme Q10 (CoQ10, ubiquinone) formulations are often of poor intestinal absorption. The relative bioavailability of CoQ10 has been shown in National Institutes of Health-funded clinical trials to be increased by its delivery system. We investigated the bioavailability of a new CoQ10 formulation based on a new and patented technology, VESIsorb, with 3 other commercially available CoQ10 products, an oil-based formulation and 2 solubilizates. This new CoQ10 formulation (commercially branded CoQsource) is a lipid-based formulation that naturally self-assembles on contact with an aqueous phase into an association colloid delivery system (hereafter "colloidal-Q10"). Twenty healthy male and female subjects participated in a double-blind, comparative (parallel design), controlled, single-dose (120 mg) bioavailability study. Plasma concentration of CoQ10 was determined at baseline and at various intervals after administration over a 24-hour period. To compare bioavailability, maximum concentration (Cmax) and area under curve from 0 to 10 hours (AUC(0-10h)) were assessed. The kinetic profiles of all CoQ10 preparations revealed a 1-peak plasma concentration-time course. Highest Cmax values were seen after colloidal-Q10 administration. Colloidal-Q10 not only had the highest plasma concentration levels after 1 hour, but it continued to increase before reaching Cmax at about 4 hours. The plasma concentration of colloidal-Q10 remained well above the levels of the 3 other products throughout the 24-hour period. The relative bioavailability calculated using the AUC(0-10h) values was also the highest for colloidal-Q10; the AUC(0-10h) values were 30.6, 6.1, 4.9, and 10.7 microg/mL*h for colloidal-Q10, solubilizate 1, the oil-based formulation, and solubilizate 2, respectively. Differences in Cmax and AUC between colloidal-Q10 and the 3 other formulations were statistically significant. In summary, the data presented suggests that colloidal-Q10 improves the enteral absorption and the bioavailability of CoQ10 in humans.

Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10)

Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system

Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals

A New Food-grade Coenzyme Q10 Formulation Improves Bioavailability: Single and Repeated Pharmacokinetic Studies in Healthy Volunteers

Bioavailability of coenzyme Q10 loaded in an oleogel formulation for oral therapy: Comparison with a commercial-grade solid formulation

Enhancing solubility and bioavailability of coenzyme Q10: formulation of solid dispersions using Soluplus® as a carrier

Bioavailability enhancement of coenzyme Q10: An update of novel approaches

The Cocrystal of Ubiquinol: Improved Stability and Bioavailability

Novel Lipid-Free Nanoformulation for Improving Oral Bioavailability of Coenzyme Q10.

Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism

CoQ10 Bioaccessibility and Caco-2 Cell Uptake Improved with Novel Medium Chain Triglyceride Encapsulation

Relative Bioavailability Assessment of Oral Coenzyme Q10 Formulations in Beagle Dogs

Comparison of uptake between PureSorb-Q40 and regular hydrophobic coenzyme Q10 in rats and humans after single oral intake

PEGylated Solanesol for Oral Delivery of Coenzyme Q10

Total Coenzyme Q10 Concentrations in Asian Men Following Multiple Oral 50-Mg Doses Administered As Coenzyme Q10 Sustained Release Tablets or Regular Tablets.

Emulsification using highly hydrophilic surfactants improves the absorption of orally administered coenzyme Q10

Evaluation of pharmacokinetic parameters of ubiquinol acetate, ubiquinone and ubiquinol in male Sprague-Dawley rats – A comparative study

Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations

Characterization and pharmacokinetics of coenzyme Q 10 nanoparticles prepared by a rapid expansion of supercritical solution process

PEGylated Solanesol for Oral Delivery of Coenzyme Q 10 .

Improvement of the Oral Bioavailability of Coenzyme Q10 with Lecithin Nanocapsules.